SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-21-067091
Filing Date
2021-12-22
Accepted
2021-12-22 17:21:54
Documents
14
Period of Report
2021-12-22
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea152954-8k_relmada.htm   iXBRL 8-K 28037
2 PRESS RELEASE DATED DECEMBER 22, 2021 ea152954ex99-1_relmada.htm EX-99.1 17323
3 GRAPHIC ex99-1_001.jpg GRAPHIC 11672
  Complete submission text file 0001213900-21-067091.txt   239003

Data Files

Seq Description Document Type Size
4 XBRL LABEL FILE rlmd-20211222_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE rlmd-20211222_pre.xml EX-101.PRE 22357
6 XBRL SCHEMA FILE rlmd-20211222.xsd EX-101.SCH 3022
8 EXTRACTED XBRL INSTANCE DOCUMENT ea152954-8k_relmada_htm.xml XML 3620
Mailing Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134
Business Address 2222 PONCE DE LEON BLVD. 3RD FLOOR CORAL GABLES FL 33134 646 876 3459
RELMADA THERAPEUTICS, INC. (Filer) CIK: 0001553643 (see all company filings)

IRS No.: 455401931 | State of Incorp.: NV | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39082 | Film No.: 211514099
SIC: 2834 Pharmaceutical Preparations